Vaishali Pharma
NSE: VAISHALI · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vaishali Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vaishali Pharma Limited is an ISO 9001:2008 certified company engaged in the marketing and distribution of a diverse range of pharmaceutical products. Its portfolio encompasses over 1,500 products and 250 brands, spanning APIs, formulations, surgical supplies, herbals, veterinary products, and oncology treatments.
Business Model
The company operates as a pharmaceutical marketer, leveraging a broad product portfolio to serve healthcare needs across multiple therapeutic segments. It generates revenue through the distribution and sale of its extensive range of branded and generic healthcare products.
- Product Portfolio:1500+ products
- Brand Count:250+ brands
- Operational Reach:35+ locations
Growth Outlook
The company aims to leverage its extensive product range and established distribution network to expand its market presence. Future growth is expected to be driven by the continued scaling of its diverse healthcare segments, including oncology and nutraceuticals.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical regulations and quality standards, where any failure to maintain certifications could disrupt operations.
- Market Competition. The pharmaceutical marketing sector is highly competitive, potentially impacting profit margins and market share.
- Supply Chain Dependency. Reliance on third-party manufacturers for a wide range of products exposes the company to risks related to supply chain disruptions and quality control.
- Geopolitical and Currency Risk. Operating across multiple locations subjects the company to fluctuations in foreign exchange rates and international trade policy changes.
Start your research today
Unlock AI insights, financials, peers and live data on Vaishali Pharma and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Vaishali PharmaVAISHALI | ₹110 Cr | -31.04 | 16.04 | — | 7.3% | 6.1% | 10.4% | -26.7% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Vaishali Pharma
NSE: VAISHALI · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vaishali Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vaishali Pharma Limited is an ISO 9001:2008 certified company engaged in the marketing and distribution of a diverse range of pharmaceutical products. Its portfolio encompasses over 1,500 products and 250 brands, spanning APIs, formulations, surgical supplies, herbals, veterinary products, and oncology treatments.
Business Model
The company operates as a pharmaceutical marketer, leveraging a broad product portfolio to serve healthcare needs across multiple therapeutic segments. It generates revenue through the distribution and sale of its extensive range of branded and generic healthcare products.
- Product Portfolio:1500+ products
- Brand Count:250+ brands
- Operational Reach:35+ locations
Growth Outlook
The company aims to leverage its extensive product range and established distribution network to expand its market presence. Future growth is expected to be driven by the continued scaling of its diverse healthcare segments, including oncology and nutraceuticals.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical regulations and quality standards, where any failure to maintain certifications could disrupt operations.
- Market Competition. The pharmaceutical marketing sector is highly competitive, potentially impacting profit margins and market share.
- Supply Chain Dependency. Reliance on third-party manufacturers for a wide range of products exposes the company to risks related to supply chain disruptions and quality control.
- Geopolitical and Currency Risk. Operating across multiple locations subjects the company to fluctuations in foreign exchange rates and international trade policy changes.
Start your research today
Unlock AI insights, financials, peers and live data on Vaishali Pharma and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Q4 FY26